Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.
about
Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment ComparisonHealth-related quality of life measurement in asthma and chronic obstructive pulmonary disease: review of the 2009-2014 literaturePharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial AsthmaComparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysisPositioning new pharmacotherapies for COPDTen years of tiotropium: clinical impact and patient perspectivesProfile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPDLong-acting muscarinic receptor antagonists for the treatment of chronic airway diseasesClinical potential of aclidinium bromide in chronic obstructive pulmonary diseaseThe Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary DiseasePharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewThe association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysisA randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPDSafety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use.Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trialsRandomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.COPD: maximization of bronchodilation.A novel model-based approach for dose determination of glycopyrronium bromide in COPDImplementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions.Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trialProfile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.The role of bronchodilator treatment in the prevention of exacerbations of COPD.One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.Pharmacotherapies for COPD.Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)Role of once-daily glycopyrronium bromide (NVA237) in the management of COPDComparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyEligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.
P2860
Q26765425-C1722D70-FC34-4413-A854-B4B9C016ADE4Q26765780-1BD0DB6B-EA25-43A3-9F4D-28E7E5A1571EQ26777927-08DD0E31-09FB-43DB-8D4A-82D5A7223BCCQ26780553-A696A786-9D88-417D-BB3B-3190A631DC5EQ26782484-A3EA3DC4-1583-453D-A7D9-6956E8303F6AQ26798659-6039CB58-211B-4933-8A85-F54C13750A74Q26823682-00011B6F-5B8D-403F-9974-FC712691F816Q26825822-2BA1C812-F1F0-4DB2-83FB-A60FF23C1EC1Q27022636-E323112A-BCF8-4B6E-81A2-F2ADE98ED175Q27023223-008565C7-C73A-4F02-9B34-B4380E96F0AEQ28068078-01A86C9C-6A7F-4667-BA38-C9F1E6510C2DQ28070274-421050D5-E207-43B1-BE40-06B219642AF8Q28070325-9FD71046-CBFA-4B64-BE5D-20B6BB30F6C9Q28596637-5370A0AB-EF3E-45C5-887B-8796BD877B79Q30990525-5476F571-69C3-4474-96FD-46D8CEEB3EFAQ33167296-55E441B7-EA78-4863-B3F9-45EBE019C8DCQ33824534-99065D33-F479-4371-BBB3-E1F1650989D5Q34012174-5DCFB370-5558-4355-8D42-0F007FAA4300Q34336907-E0F2CE79-9332-475C-B6BD-241643A37406Q34436393-CBCAF684-6CCD-424C-8064-1E0EB84B372AQ34502782-FD937619-669B-47F4-9967-D3C675B114CFQ34628637-1A60CD3B-F1D4-42BE-8AE0-B59B91C63B15Q34944547-F670854D-CCC5-4399-969F-A5BA0F6E4BABQ35135970-1765C229-F099-4314-A162-5FC6D080645DQ35538249-2E13F022-414A-464D-93AC-05BC5A71F936Q35595077-89F83BA7-0383-4913-9C3A-C4C3B21E399EQ35766346-237F3EA4-4445-4172-BAB2-025BA1B01DD5Q36302882-D630001B-4BB0-4645-B8ED-0420746D4270Q36307097-C6D5579D-8EB2-40F7-A305-9021D64BF571Q36356295-6E1ADAE4-EC57-4F6C-997F-0AACDAA1E808Q36438669-41B1E37D-2456-4A18-A55B-8E2B6011AE55Q36652462-F394D397-A258-4E31-A639-97899C9A203EQ36843717-0AF2136F-4A03-4DA8-BCC7-ECDCFBF17FD1Q37003186-2B57709B-58D5-4D63-AB20-A44124D64416Q37069374-BA24B68E-92F4-4CFC-AD56-46503E59C9A9Q37120706-BD3257D0-0BAA-4A58-8CCE-259C898A6821Q37170227-6B2F574A-D320-44FF-BF28-7D2385DE5D7DQ37228266-B79AA078-5075-40D4-A19A-067CEA6E5E3EQ37247499-AB57A5C3-6AA1-4C99-BA73-ABBA334FE247Q37278903-219763B6-E63E-458D-8E26-E18E7D95FE34
P2860
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Efficacy and safety of NVA237 ...... ts with COPD: the GLOW2 study.
@ast
Efficacy and safety of NVA237 ...... ts with COPD: the GLOW2 study.
@en
type
label
Efficacy and safety of NVA237 ...... ts with COPD: the GLOW2 study.
@ast
Efficacy and safety of NVA237 ...... ts with COPD: the GLOW2 study.
@en
prefLabel
Efficacy and safety of NVA237 ...... ts with COPD: the GLOW2 study.
@ast
Efficacy and safety of NVA237 ...... ts with COPD: the GLOW2 study.
@en
P2093
P2860
P921
P1476
Efficacy and safety of NVA237 ...... ts with COPD: the GLOW2 study.
@en
P2093
Carmen Martin
Donald Banerji
Edward Kerwin
Jacques Hébert
Nicola Gallagher
Tim Overend
Vijay K T Alagappan
P2860
P304
P356
10.1183/09031936.00040712
P577
2012-07-26T00:00:00Z